Ian Lopez is a Senior Reporter specializing in health news. His work has been featured in Bloomberg Law, Winnipeg Sun, and Lexology. Ian covers a wide range of topics related to healthcare, including drug pricing, healthcare policy, and pharmaceutical industry developments.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Ian Lopez's coverage predominantly focuses on healthcare and pharmaceuticals with a significant emphasis on legal policy regulation and government announcements related to the industry. He covers topics such as drug pricing, healthcare policy, pharmaceutical industry news, lawsuits, and developments within the Biden administration.
Given his focus on legal policy regulation in the context of healthcare and pharmaceuticals, Ian would likely be interested in pitches that offer insights from experts or stakeholders involved in these areas. This could include legal professionals specializing in healthcare law or individuals with direct experience navigating regulatory challenges within the pharmaceutical industry.
Considering his extensive coverage of government announcements pertaining to healthcare policies and regulations, relevant sources might include policymakers, advocacy groups focused on drug pricing reforms or access to medications, as well as executives from pharmaceutical companies impacted by regulatory changes.
As Ian does not have a specific geographic focus mentioned but primarily covers national (US) issues related to politics and health care policies at large federal levels including those concerning FDA approvals for medical drugs.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ian Lopez, Nyah Phengsitthy
Sen. Elizabeth Warren (D-Mass.) and Rep. Pramila Jayapal (D-Wash.) are pressuring the Federal Trade Commission to take action against drugmakers for allegedly abusing the patent system to cut down competition and keep costs high, in a letter to FTC Chair Lina Khan that was first shared with Bloomberg Law.
Medicare’s first-ever drug pricing negotiation process could be shaken by a looming government shutdown, Health and Human Services Secretary Xavier Becerra said Friday.
The Biden administration agreed to begin enforcing a Trump-era drug price transparency rule on the date it was supposed to go into effect, a move that follows a legal challenge brought by the conservative think tank Foundation for Government Accountability.
The Biden administration is seeking input on whether to require insurers to cover over-the-counter preventive care services and treatments that don’t require a prescription, a category that encompasses birth control, smoking cessation products, and Covid-19 tests.
A major pharmaceutical industry lobby is wading into a potential US Supreme Court battle over access to the abortion medication mifepristone, warning the justices that lower court restrictions invite litigation that could disrupt drug development.
Individuals who say they were injured by Covid-19 vaccines are suing the Biden administration over a payout process that shields drug companies from lawsuits, saying it’s unconstitutional and deprives them of their right to a jury trial.
Pharmaceutical industry watchers are split on whether Astellas Pharma’s Xtandi will continue to be targeted by attempts to lower drug prices following the prostate cancer treatment’s absence on the Biden administration’s list of drugs subject to Medicare negotiations.
Conservative physician groups that succeeded in getting restrictions on the abortion drug mifepristone are now urging the US Supreme Court to undo the Food and Drug Administration’s approval of the drug.
By: Ian Lopez
(Bloomberg Law) — The Biden administration will allow Florida to import cheaper prescription drugs from Canada, giving the green light to a plan put in motion by the state several years ago.
The Biden administration will allow Florida to import cheaper prescription drugs from Canada, giving the green light to a plan put in motion by the state several years ago.
(833) 317-6278 
